Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis.
Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis.
复制标题
DOI：
10.2217/fon.12.57
复制
发表时间：
2012-06
期刊：
影响因子：
--
通讯作者：
Wang XY
中科院分区：
文献类型：
--
作者：
Manjili MH;Najarian K;Wang XY
乳腺癌死亡率通常是由于癌症晚期的远处复发，而不是原发性癌症。因此，在诊断时预测乳腺癌复发可能会导致癌症患者个性化治疗的进步，以防止复发风险。目前在临床实践中使用的两种预后生物标志物是70个基因的MammaPrint®签名和21个基因的Oncotype DX®面板。这些测定产生复发的相对风险，但它们不提供关于给定患者的复发的"是"或"否"答案。这些检测包括与乳腺癌相关的细胞周期、侵袭、转移和血管生成相关的基因。新出现的证据表明，参与肿瘤-免疫相互作用的基因的特征可能提供更准确的预后工具。本文就乳腺癌预后生物标志物的研究进展作一综述。
Breast cancer mortality is usually due to distant recurrence of cancer at an advanced stage of the disease rather than from primary cancer. Therefore, prediction of breast cancer recurrence at the time of diagnosis could lead to advances in personalized treatment of cancer patients in order to prevent risk of recurrence. Two prognostic biomarkers that are currently being used in clinical practice are a 70-gene MammaPrint® signature and a 21-gene Oncotype DX® panel. These assays generate relative risks of recurrence, but they do not provide a ‘yes’ or ‘no’ answer about recurrence in a given patient. These tests include genes that are involved in the cell cycle, invasion, metastasis and angiogenesis related to breast cancer. Emerging evidence suggests that a signature of genes involved in tumor-immune interactions may provide a more accurate prognostic tool. This paper reviews recent advances in the discovery of prognostic biomarkers for breast cancer patients.